Opinion|Videos|March 18, 2024
Testing for MRD in Colorectal Cancer
Focusing on the adjuvant setting, the expert panel discusses the timing and frequency of MRD testing in patients with colorectal cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
The CDH17-targeting antibody-drug conjugate received the designation for previously treated advanced unresectable or metastatic colorectal cancer.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
2
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
3
Dr Galsky on Systemic Therapy Advances in Muscle-Invasive Bladder Cancer
4
Dr Patel on the Unmet Need in EGFR+ Transformed Small Cell Lung Cancer
5